BridgeBio Oncology Therapeutics
Update in progressBBOT (NasdaqGM)
- SectorHealthcare
- IndustryBiotechnology
BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company developing orally available small-molecule drugs. Its pipeline includes BBO-8520, a direct KRASG12C inhibitor in Phase I for KRASG12C mutant NSCLC; BBO-11818, a pan-KRAS inhibitor in Phase I for KRAS G12D/G12V models; and BBO-10203 in Phase I for HER2+ and HR+/HER2- breast cancer, plus KRAS mutant CRC and NSCLC, along with precision oncology assets. Founded in 2016, based in South San Francisco, California.
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!